Literature DB >> 10927941

Hepatobiliary involvement of Henoch-Schönlein purpura in children.

H C Chao1, M S Kong, S J Lin.   

Abstract

Hepatobiliary manifestation and its evolution in children with Henoch-Schönlein purpura (HSP) had been scarcely reported. Over a ten-year period between June 1988 and November 1998, medical charts of 225 children with the diagnosis of HSP encountered at Chang Gung Children's Hospital were reviewed. Those with the evidence of hepatobiliary involvement were enrolled in the study. The patients with hepatobiliary involvement were defined by having an elevated serum alanine transaminase (ALT) or gamma-glutamyl transferase (GGT), and the presence of abnormal sonographic findings involving liver, biliary system, and gallbladder. The patients included 9 boys and 11 girls with range of age from 3 to 11 years. The mean age of these patients was 6.5 +/- 3.7 years. Preceding upper respiratory tract infection was common in these patients (35%). The main clinical manifestation were distinct from typical abdominal symptoms of HSP, and included right upper quadrant pain (80%), nausea (45%), lethargy (20%), and vomiting (15%). Elevated serum ALT was noted in 15 cases (75%) and GGT in 6 cases (30%). Abdominal ultrasonography revealed hepatomegaly (15/20, 75%), and gallbladder wall thickening (5/20, 25%). No specific laboratory parameters were correlated with the hepatobiliary manifestation of HSP. Fourteen children (70%) received steroid therapy and disappearance of symptoms and sonographic resolution of hepatobiliary lesion was noted within 3-7 days of steroid therapy. All patients recovered completely except for one patient with hepatobiliary recurrence manifested as purpuric rash, abdominal pain, elevated GGT, and gallbladder wall thickening during 2-year follow-up.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10927941

Source DB:  PubMed          Journal:  Acta Paediatr Taiwan        ISSN: 1608-8115


  9 in total

Review 1.  Multisystemic manifestations of IgA vasculitis.

Authors:  Lina Du; Panpan Wang; Chang Liu; Shaojing Li; Shuang Yue; Yan Yang
Journal:  Clin Rheumatol       Date:  2020-06-16       Impact factor: 2.980

Review 2.  Gastrointestinal manifestations of Henoch-Schonlein Purpura.

Authors:  Ellen C Ebert
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

Review 3.  Gastrointestinal aspects of vasculitides.

Authors:  Medha Soowamber; Adam V Weizman; Christian Pagnoux
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-23       Impact factor: 46.802

Review 4.  Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review.

Authors:  Pamela F Weiss; James A Feinstein; Xianqun Luan; Jon M Burnham; Chris Feudtner
Journal:  Pediatrics       Date:  2007-11       Impact factor: 7.124

Review 5.  IgA Vasculitis in Adults: a Rare yet Challenging Disease.

Authors:  Kinanah Yaseen; Leal C Herlitz; Alexandra Villa-Forte
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

6.  Liver chemistry in new-onset Henoch-Schönlein syndrome.

Authors:  Giulia Rosti; Gregorio P Milani; Emanuela A Laicini; Emilio F Fossali; Mario G Bianchetti
Journal:  Ital J Pediatr       Date:  2017-09-21       Impact factor: 2.638

7.  Proteomic analysis of urine reveals biomarkers for the diagnosis and phenotyping of abdominal-type Henoch-Schonlein purpura.

Authors:  Lulu Jia; Jianqiang Wu; Jing Wei; Lina Du; Panpan Wang; Yanju Zhang; Yuncui Yu; Xiaoling Wang; Yan Yang; Youhe Gao
Journal:  Transl Pediatr       Date:  2021-03

Review 8.  Henoch-Schönlein Purpura in an Obese Adult with Elevated Transaminase: A Case Report and Literature Review.

Authors:  Andrew Limavady; Ketut Suryana
Journal:  Ethiop J Health Sci       Date:  2022-07

Review 9.  Imaging of intestinal vasculitis focusing on MR and CT enterography: a two-way street between radiologic findings and clinical data.

Authors:  Mehrnam Amouei; Sara Momtazmanesh; Hoda Kavosi; Amir H Davarpanah; Ali Shirkhoda; Amir Reza Radmard
Journal:  Insights Imaging       Date:  2022-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.